Horizon Discovery
Dr. Kadia has a deep background in executive management and public company governance across a range of global businesses, predominantly in the Life Sciences Tools, Diagnostics and Medical Technologies, High Tech and TIC (Testing, Inspection and Certification) industries. Dr. Kadia was formerly President and CEO of EAG Laboratories until its acquisition by Eurofins Scientific in 2017. He continued to serve as the CEO of EAG laboratories until December 2018. Prior to EAG, he served in a number of senior roles including as President of Life Sciences Division at Life Technologies Corporation at the time of its acquisition by ThermoFisher Scientific in February 2014.
Dr. Kadia has extensive Board experience and has previously served as a Director of two US listed companies, Newport Corporation (NSDQ: NEWP), Volcano Corporation (NSDQ: VOLC) and of privately owned EAG Laboratories. Dr. Kadia has executive experience leading businesses in the US, Europe, Japan and China and has an extensive global network in scientific enterprise.
Dr. Kadia obtained his Ph.D. in biomedical engineering from Johns Hopkins University, followed by a post-doctoral fellowship at Johns Hopkins University School of Medicine, Baltimore. He also holds a M.S. in biomedical engineering from Rutgers University, New Jersey, and a B.E in electronics and telecommunications from Gujarat University in India.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Horizon Discovery
2 followers
Horizon builds human disease models and reagents derived from genetically-engineered cells that its customers use, or that are deployed on their behalf to: gain knowledge of the genetic drivers of disease; develop novel drugs or cell therapies targeted.